$0.28 EPS Expected for Myriad Genetics, Inc. (MYGN)

October 11, 2018 - By Louis Casey

Myriad Genetics, Inc. (NASDAQ:MYGN) LogoInvestors sentiment decreased to 0.95 in 2018 Q2. Its down 0.48, from 1.43 in 2018Q1. It turned negative, as 25 investors sold Myriad Genetics, Inc. shares while 80 reduced holdings. 35 funds opened positions while 65 raised stakes. 71.11 million shares or 1.16% less from 71.94 million shares in 2018Q1 were reported.
Cs Mckee Ltd Partnership reported 37,250 shares stake. 3,998 were accumulated by Bnp Paribas Arbitrage. Moreover, Voloridge Inv Management Lc has 0.09% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 88,090 shares. New York State Common Retirement Fund holds 0.01% or 213,914 shares in its portfolio. Pinebridge Invests L P has 0.01% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Hall Laurie J Trustee reported 200 shares or 0% of all its holdings. Alliancebernstein Limited Partnership has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Globeflex Cap Lp stated it has 21,230 shares or 0.16% of all its holdings. Baillie Gifford And invested 0.38% in Myriad Genetics, Inc. (NASDAQ:MYGN). Tiaa Cref Investment Ltd Liability Co, a New York-based fund reported 146,500 shares. The North Carolina-based Comml Bank Of America Corporation De has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Goldman Sachs Gru holds 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN) or 1.07 million shares. Aimz Investment Advsr Limited Company reported 43,985 shares. Hsbc Public Ltd reported 15,900 shares stake. Sei Investments stated it has 1,929 shares.

Since May 21, 2018, it had 0 buys, and 13 selling transactions for $22.83 million activity. LANCHBURY JERRY S sold $2.17M worth of stock. 90,000 shares valued at $3.42M were sold by Capone Mark Christopher on Wednesday, May 30. $379,245 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) was sold by LANGER DENNIS. 30,000 shares were sold by HENDERSON JOHN T, worth $1.26 million on Wednesday, July 11. GILBERT WALTER PHD also sold $1.19 million worth of Myriad Genetics, Inc. (NASDAQ:MYGN) shares.

Analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to report $0.28 EPS on November, 6.They anticipate $0.02 EPS change or 7.69 % from last quarter’s $0.26 EPS. MYGN’s profit would be $19.85M giving it 40.05 P/E if the $0.28 EPS is correct. After having $0.38 EPS previously, Myriad Genetics, Inc.’s analysts see -26.32 % EPS growth. The stock increased 3.87% or $1.67 during the last trading session, reaching $44.86. About 997,141 shares traded or 29.82% up from the average. Myriad Genetics, Inc. (NASDAQ:MYGN) has risen 45.52% since October 11, 2017 and is uptrending. It has outperformed by 29.90% the S&P500.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

Among 4 analysts covering Myriad Genetics (NASDAQ:MYGN), 1 have Buy rating, 2 Sell and 1 Hold. Therefore 25% are positive. Myriad Genetics had 10 analyst reports since May 9, 2018 according to SRatingsIntel. Bank of America maintained Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Wednesday, August 22. Bank of America has “Underperform” rating and $34 target. The rating was downgraded by Barclays Capital to “Underweight” on Wednesday, September 5. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, May 9. The company was maintained on Wednesday, August 22 by Morgan Stanley. Leerink Swann maintained the stock with “Hold” rating in Tuesday, May 29 report. Leerink Swann maintained the shares of MYGN in report on Tuesday, August 28 with “Market Perform” rating. The rating was upgraded by Morgan Stanley on Wednesday, July 11 to “Overweight”. The rating was maintained by Bank of America with “Underperform” on Monday, July 16. Barclays Capital maintained the stock with “Equal-Weight” rating in Wednesday, August 22 report. The stock has “Underweight” rating by Barclays Capital on Tuesday, September 11.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $3.18 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 24.65 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: Streetinsider.com which released: “Myriad Genetics (MYGN) announces it signed commercialization plan with Pfizer (PFE)” on October 09, 2018, also Benzinga.com with their article: “41 Stocks Moving In Wednesday’s Mid-Day Session” published on October 10, 2018, Globenewswire.com published: “Detailed Research: Economic Perspectives on MTS, Delek US, Alarm, Strongbridge Biopharma, Myriad Genetics, and …” on October 09, 2018. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: Streetinsider.com and their article: “Piper Jaffray Upgrades Myriad Genetics (MYGN) to Overweight” published on October 10, 2018 as well as 247Wallst.com‘s news article titled: “Top Analyst Upgrades and Downgrades: Agilent, Alibaba, CRISPR, Iridium, McDonald’s, Myriad Genetics, Shake …” with publication date: October 10, 2018.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: